Skip to content

#AI制药

Today 0 items
Oct 15Thu
  1. biospace.com69

    AstraZeneca bulks up MASH, cardio work in up to $1.5B AI partnership with insitro

    AstraZeneca will pay insitro up to $1.5 billion to discover drug targets for metabolic dysfunction-associated steatohepatitis and cardiomyopathies using insitro's Virtual Human AI platform. Insitro receives $40 million upfront and up to $1.46 billion in milestones plus royalties, while AstraZeneca advances any candidates through development. The deal adds to AstraZeneca's MASH work, which includes the Phase 1 anti-fibrotic asset AZD2389.

    Why it matters: A large pharma-AI target discovery deal in MASH and cardiomyopathies, indications where AstraZeneca has recent setbacks.

  2. biopharmadive.com61

    Iambic, an AI drug discovery specialist, banks $150M in an IPO

    Iambic Therapeutics, an AI drug discovery startup, raised $150 million in an IPO, selling close to 9.4 million shares at $16 each and trading on the Nasdaq from Thursday under the ticker "IAM." The company has drawn $462 million in private funding since 2019 and will use the proceeds to advance its first drug, IAM1363, an oral tyrosine kinase inhibitor for HER2-positive solid tumors that showed anti-tumor activity and encouraging safety in a Phase 1 study, with a registrational trial possibly beginning in 2027. Behind it are IAM217, targeting KIF18A in ovarian and triple-negative breast cancers, and a CDK2/CDK4-targeting prospect, both potentially entering testing next year.

    Why it matters: The offering adds to a wave of AI drug discovery startups testing whether public investors will back the technology.

Oct 14Wed
  1. biospace.com63

    Zealand pens up to $1.2B deal with Generate for AI-designed obesity, metabolic drugs

    Zealand Pharma will pay Generate:Biomedicines $30 million upfront, up to $35 million in early preclinical milestones and nearly $1.2 billion in development, regulatory and commercial milestones, plus tiered royalties, to access Generate's generative AI platform for designing protein therapeutics for obesity and metabolic diseases. Generate handles research through candidate selection; Zealand leads clinical development, regulatory and commercialization. The deal follows mixed Zealand readouts for petrelintide and survodutide.

    Why it matters: Large AI drug-discovery alliance in obesity adds Generate's platform to Zealand's metabolic pipeline after mixed trial results.

Oct 13Tue
  1. biospace.com56

    Pfizer pens $500M+ deal with Enodia to destroy disease-causing proteins

    Pfizer has signed a deal with Paris-based Enodia Therapeutics worth up to $500 million, covering an upfront payment plus research, development and sales milestones, with tiered royalties on net sales. Enodia will screen, optimize and develop small-molecule inhibitors of the Sec61 membrane protein complex, while Pfizer handles clinical studies, manufacturing, regulatory and commercial work. Target indications are not yet specified. Pfizer's venture arm had co-led Enodia's €20.7 million ($25 million) seed round in January.

    Why it matters: Pfizer commits over $500 million to a Sec61-targeting platform less than a year after the biotech's launch.

Oct 9Fri
  1. biospace.com54

    TRexBio, Retension raise $161.7M in IPOs; City, Iambic set proposed offering terms

    TRexBio raised $116.7 million in its Nasdaq IPO, selling 8.3 million shares at $14 to fund TRB-061, a fusion protein in early-stage development for atopic dermatitis with a Phase 1b topline readout expected mid-2027. Retension Pharmaceuticals raised $45 million at $12 per share to advance RTN-001, a PDE-5 blocker for hypertension, through Phase 2b and into Phase 3. City Therapeutics expects about $158.3 million and Iambic Therapeutics about $135 million from upcoming offerings.

    Why it matters: Four biotech IPOs in one week signal a reopening of the public markets for drug developers.

Oct 8Thu
  1. biospace.com66

    Big Pharma–backed Matchpoint scores $150M series B, advancing autoimmune asset

    Preclinical Matchpoint Therapeutics has raised a $150 million series B co-led by Nextech Invest and Norwest, with participation from Sanofi Ventures, Atlas Venture, Access Biotechnology and the T1D Fund. The money will advance MPT-062, an oral T cell modulator for autoimmune and inflammatory conditions, into human trials starting next year. Matchpoint also has a July 2025 deal with Novartis, which paid $60 million upfront for its ACE platform and could owe up to $1 billion in milestones plus royalties.

    Why it matters: A large series B funds a first-in-class oral autoimmune program before it reaches human trials, against a market trend favouring later-stage assets.

Oct 6Tue
  1. biospace.com46

    Compliance concerns hinder rollout of AI in drug manufacturing: Survey

    Fewer than 10% of drugmakers are scaling AI in clinical or commercial manufacturing, according to a CRB survey of more than 400 R&D and manufacturing professionals for its 2026 Horizons report. Use is concentrated in nonregulated areas such as administrative workflows (56%) and drug discovery (45%), with accuracy and quality concerns and insufficient validation standards cited as the main barriers. CRB found that 31% of respondents plan to use AI in regulated manufacturing within three years, and another 31% are considering it without a formal plan.

    Why it matters: Shows regulatory and validation concerns are blocking AI adoption in drug manufacturing, with an FDA warning letter already issued.

Sep 22Tue
  1. FierceBiotech44

    Iambic maintains momentum from string of Big Pharma partnerships by aiming for IPO

    Iambic Therapeutics, a San Diego AI drug discovery biotech, has filed with the SEC to go public after raising a $100 million series B in 2023 and a similar round in November 2025. IPO proceeds would chiefly fund IAM1363, an oral brain-penetrant HER2 inhibitor in a phase 1 study in advanced HER2-altered solid tumors, with a registrational trial planned for early 2027. The company had $207.9 million in the bank at the end of June and partnerships including a Takeda deal worth up to $1.7 billion.

    Why it matters: An AI drug discovery biotech with large pharma deals and $1.7 billion in Takeda biobucks is moving toward an IPO.

Aug 14Fri
  1. STAT News53

    STAT+: Commure terminates payments under its customer referral programs tied to AI products

    Commure, a $7 billion health software company based in Mountain View, Calif., has terminated its customer referral program that paid parties to refer its AI products to new business prospects. Company emails from chief legal officer Dan Brian, dated Aug. 6, 2026, say payment agreements end 30 days from receipt of notice and that amounts owed will be paid in full. The move came six days before a STAT investigation into the arrangements, which STAT had first queried on June 5.

CBACBA Frontier Insights (CFI)Chinese Biopharmaceutical Association (CBA)www.cba-usa.org